Durability Of Responses After Sars-Cov-2 Mrna-1273 Vaccination Alicia T. Widge , Nadine G. Rouphael , Lisa A. Jackson , Evan J. Anderson , Paul C. Roberts , Mamodikoe Makhene , James D. Chappell , Mark R. Denison , Laura J. Stevens , Andrea J. Pruijssers , Adrian B. McDermott , Britta Flach , Bob C. Lin , Nicole A. Doria-Rose , Sijy O’Dell , Stephen D. Schmidt , Kathleen M. Neuzil , Hamilton Bennett , Brett Leav , Mat Makowski , Jim Albert , Kaitlyn Cross , Venkata-Viswanadh Edara , Katharine Floyd , Mehul S. Suthar , Wendy Buchanan , Catherine J. Luke , Julie E. Ledgerwood , John R. Mascola , Barney S. Graham , John H. Beigel NEW ENGLAND JOURNAL OF MEDICINE（2021）
摘要
Immunogenicity and Moderna’s SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers...
更多 查看译文
AI 理解论文
溯源树
样例
